# Harmony Biosciences Holdings, Inc. (HRMY)

> Source: Nexqual · https://nexqual.com/HRMY · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Harmony Biosciences Holdings, Inc. (HRMY), nexqual.com/HRMY" · informational, not investment advice.

**Price:** USD 38.59 (+0.23% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 38.5 · day 38.04–39.2 · 52w 25.9–43.49 · market cap $2.25B · NGM

## Key facts
- Valuation: P/E 12.4x (avg 14.2x at the last 3 fiscal year-ends), net cash $514M.
- Analysts: Buy (mean 2.33 on a 1–5 scale) (12 analysts), mean target USD 48.25 (range 30–70).
- Total return with dividends: 1Y +33.2% vs S&P 500 +14.8%; 5Y -6.9% vs S&P 500 +79.1%.
- Next earnings: 2026-11-04, EPS estimate USD 1.47, revenue estimate $273M. All companies reporting that day: https://nexqual.com/earnings/2026-11-04
- Dividend: HRMY paid no cash dividend in the last five years.
- Short interest: 12.42% of float (as of 2026-10-15), 5.3 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 12.4x · P/S 2.3x · EV/Sales 1.8x · P/B 2.2x · Earnings yield 8.08% · Net cash $514M · EV $1.73B
P/E at fiscal year-ends: Dec 2025 13.8x, Dec 2024 13.7x, Dec 2023 15.1x.

## Analysts
Consensus Buy (mean 2.33 on a 1–5 scale), 12 analysts; mean target USD 48.25 (low 30, high 70).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Needham | Reiterated | Buy | $50 |
| 2026-10-13 | HC Wainwright & Co. | Reiterated | Buy | $55 |
| 2026-10-12 | Needham | Reiterated | Buy | $50 |
| 2026-08-26 | Wolfe Research | Initiated | Outperform | $60 |
| 2026-08-05 | Truist Securities | Target raised | Hold | $29 → $34 |
| 2026-08-04 | Needham | Target raised | Buy | $45 → $50 |
| 2026-07-31 | Mizuho | Target raised | Outperform | $50 → $51 |
| 2026-07-16 | HC Wainwright & Co. | Reiterated | Buy | $55 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +33.2% | -6.9% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +33.5% | -1.4% |
| Volatility (annualized) | 40.5% | 48.6% |
| Max drawdown | -34.5% (Dec 2025→Mar 2026) | -68.3% (Nov 2022→Oct 2023) |

## Dividends
HRMY paid no cash dividend in the last five years.

## Short interest
5,413,347 shares sold short, 12.42% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 4,628,716 shares (+17.0%). Days to cover: 5.3 (short shares ÷ average daily volume).

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/HRMY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.47 | $1.22 | +19.9% | $273.1M | 2 |
| Next quarter (ends 2026-12-31) | $1.53 | $1.56 | -1.9% | $281.0M | 2 |
| Current fiscal year (ends 2026-12-31) | $5.22 | $4.50 | +16.1% | $1.03B | 2 |
| Next fiscal year (ends 2027-12-31) | $7.00 | $6.02 | +16.4% | $1.17B | 2 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-04): ±14.1%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 71.6% | ±14.1% |
| 2026-12-18 | 50 | 50.0% | ±14.4% |
| 2027-01-15 | 78 | 66.4% | ±24.1% |
| 2027-02-19 | 113 | 70.1% | ±30.6% |
| 2027-04-16 | 169 | 64.9% | ±34.5% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $1.50 | $1.15 | Beat +30.4% | — |
| — | Quarter ended Mar 31, 2026 | $0.79 | $0.93 | Miss −15.1% | — |
| — | Quarter ended Dec 31, 2025 | $0.57 | $1.07 | Miss −46.7% | — |
| — | Quarter ended Sep 30, 2025 | $1.08 | $0.86 | Beat +25.6% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).